Prenetics announces availability of Q2 2026 shareholder letter
PRE•Q2 2026 shareholder letter highlights
- Prenetics posted its Q2 2026 shareholder letter at this link.
- Total revenue was USD 46.5 million, up 288% year over year; IM8 revenue was USD 45 million, up 359%.
- FY 2026 IM8 revenue guidance increased to USD 220 million-USD 230 million; FY 2027 IM8 revenue guidance initiated at USD 400 million+.
- July IM8 revenue reached USD 20.9 million, implying a USD 251 million annualized run-rate; consolidated adjusted free cash flow turned positive in July.
